Charles Noplis, MD
Psychiatry · la Grange, KYNPI 1639330780
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,050 of the $34,382 with a category attached, or 87.4%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 67.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $32,374 and has fallen 97.8% since, to $707 in 2025. Among psychiatry clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $365.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$23K
- AbbVie$9K
- E.r. Squibb & Sons, L.L.C.$542
- Johnson & Johnson$430
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$273
- Otsuka America Pharmaceutical, Inc.$191
- plus $502 from 11 others
What the payments were for
- Speaking & faculty fees$30,05087%
- Travel & lodging$2,0336%
- Food & beverage$2,2236%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $23,170 |
| AbbVie(2 entities) | 23 | $9,274 |
| E.r. Squibb & Sons, L.L.C. | 5 | $542 |
| Johnson & Johnson | 4 | $430 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $273 |
| Otsuka America Pharmaceutical, Inc. | 4 | $191 |
| Bausch Health US, LLC | 8 | $140 |
| Axsome Therapeutics, Inc. | 4 | $93 |
| Lundbeck LLC | 3 | $61 |
| Corium, LLC | 2 | $45 |
| Alkermes, Inc. | 2 | $44 |
| Noven Therapeutics, LLC | 2 | $37 |
| Neurocrine Biosciences, Inc. | 2 | $26 |
| Indivior Inc. | 1 | $15 |
| Orexo US, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| MDD US Operations, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRINTELLIX$22,934
- VRAYLAR$8,950
- COBENFY$389
- INVEGA SUSTENNA$315
- CAPLYTA$125
- REXULTI$122
How this compares
$34,382 in reported general payments places this provider in the 95th percentile of 348 psychiatry providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $186,224 |
| Invega SustennaPaliperidone Palmitate | 63 | $178,542 |
| Abilify MaintenaAripiprazole | 57 | $155,864 |
| Invega TrinzaPaliperidone Palmitate | 13 | $107,096 |
| VraylarCariprazine Hcl | 56 | $81,760 |
| RexultiBrexpiprazole | 41 | $71,396 |
| Lurasidone Hcl | 90 | $18,417 |
| Aripiprazole | 174 | $13,298 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 52 | $10,983 |
| Tetrabenazine | 15 | $9,319 |
| TrintellixVortioxetine Hydrobromide | 17 | $9,264 |
| Clozapine | 53 | $8,397 |
| Olanzapine | 179 | $7,169 |
| Divalproex Sodium ErDivalproex Sodium | 135 | $6,580 |
| Vilazodone Hcl | 60 | $6,527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $430 | $285,63876 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $191 | $227,26098 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $26 | $186,22424 claims |
| AbbVieVraylar | $9,274 | $81,76056 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $23,170 | $9,26417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in la Grange
- Scott Hedgesla Grange$34K
- Carmen PintoElizabethtown$1.7M
- Rifaat El-MallakhLouisville$1.6M
- Robert StewartLouisville$651K
- Mark WrightLexington$637K
- Carol MillerFrankfort$462K
- Ali FarooquiLouisville$393K
- Steven CroleyLexington$151K
- Joseph HarrisonOwensboro$131K
- Stephanie HallLouisville$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.